Hit Finding

Hit to Lead

Lead

Optimisation

Pre-clinical

Development

CMC

PARTNER

  • ELN22 85% 85%
  • ELN sc22 60% 60%
  • ELN sx201 45% 45%
  • ELN src19 60% 60%
  • ELN sxc101 60% 60%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 60% 60%
  • Bi-specific Drug Conjugate 60% 60%

Hit Finding

Hit to Lead

Lead

Optimisation

Pre-clinical

Development

CMC

PARTNER

  • ELN22 85% 85%
  • ELN sc22 60% 60%
  • ELN sx201 45% 45%
  • ELN src19 60% 60%
  • ELN sxc101 60% 60%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 60% 60%
  • Bi-specific Drug Conjugate 60% 60%